Kyverna Therapeutics Inc. (NASDAQ:KYTX) is one of the best young stocks with huge upside potential. On October 8, Wells Fargo analyst Derek Archila raised the firm’s price target on Kyverna Therapeutics to $27 from $24, while maintaining an Overweight rating on the shares. Wells Fargo likes the risk/reward on KYV-101’s pivotal stiff person syndrome trial readout in H1 2026.
The firm believes that Wall Street underappreciates how de-risked the trial is. On September 24, Kyverna Therapeutics announced that updated data from Phase 1 investigator-initiated trials/IITs of its lead candidate, KYV-101, in progressive multiple sclerosis/MS would be presented at the 2025 European Committee for Treatment and Research in Multiple Sclerosis/ECTRIMS Congress in Barcelona, Spain.
Across both IITs, KYV-101 demonstrated a tolerable safety profile, consistent with observations from the first 100 patients treated with the therapy across all indications. Notably, there were no high-grade Cytokine Release Syndrome/CRS or Immune Effector Cell Associated Neurotoxicity Syndrome/ICANS events reported, and no serious adverse events/SAEs in the Stanford study.
KYV-101 is a fully human, autologous, CD19 CAR T-cell therapy with CD28 co-stimulation, currently being investigated for its potential to deliver deep B-cell depletion and immune system reset in various B-cell-driven autoimmune diseases
Kyverna Therapeutics Inc. is a clinical-stage biopharmaceutical company that develops cell therapies for patients with autoimmune diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
